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Promoting long term adherence to antiretroviral
treatment
Patient support and community interventions are probably the best interventions
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While funders start to backtrack on financial commitments to
tackling the AIDS epidemic,
1 the HIV research community is
rallying because important steps are currently being taken in
treatment, prevention, and the combination of the two.
2 Not
since antiretroviral treatment first became available have
expectations been so high that its widespread use can break the
back of the global AIDS pandemic. Research into an HIV
vaccination has been funded for more than a decade, but long
termantiretroviraltreatmentisstillthemosteffectivebiomedical
prevention tool available.
2
For antiretroviral treatment to work as a preventive measure,
however,patientsmustconsistentlyadheretotreatment,yetour
understandingofhowtoachievewidespreadoptimaladherence
isstilllimited.Mostpeoplewhotakeantiretroviraldrugsreside
in Africa—currently, more people in the small country of
Zambia(283<thin>000)aretakingthesedrugsthaninthewhole
of the United States (268<thin>000).
3 Although most patients
in Africa adhere extremely well to treatment,
4 a proportion of
patients do not. It is important that all patients are adherent to
avoid the emergence of drug resistance, because it is not clear
thatfirstlinedrugcombinationsthatarewidelyusedinresource
limited settings offer adequate protection against drug resistant
strains.
5Onapositivenote,theriskoftreatmentfailuredeclines
withincreaseddurationofdiseasesuppressionwithantiretroviral
drugs, regardless of level of adherence,
6 which means that less
expensive first line regimens can be used for longer and
transmission to others prevented.
2
Extensive research has examined interventions aimed at
reminding patients to take their drugs, through memory tricks,
beepers, or direct observation.
7 However, emerging evidence
indicates that these techniques may not work well, and that
efforts should be channelled in a new direction. Patients with
pooradherencetolongtermtreatmentusuallyexperiencemajor
impediments to healthy behaviour in their lives. For example,
when patients are unable to provide food for their family or
schooling for their children their own health may become a
secondaryconcern.WhenpatientshavenotdisclosedtheirHIV
status to a partner it may be difficult for them to collect their
drugs or maintain their drug taking schedule. Even if patients
want to adhere to treatment they may not be able to when
pharmacies are out of stock.
8 In such cases, reminders to take
drugsmayberedundantandmayevenreinforceaselfperception
of failure.
A non-interrupted supply of drugs is key. However, a more
supportive environment may be the best approach to helping
patients overcome challenges to adherence. The authors of a
qualitative study on adherence in sub-Saharan Africa termed
such an approach—social support networks that encourage
patients to be vigilant about their health—the social capital of
adherence.
9 This may explain why patients who have disclosed
their HIV status to their partners have high levels of adherence
and why interventions aimed at community level involvement
inadherence result inrelativelylowlevels of mortalityandloss
to follow-up.
2 10 A two year follow-up of community
antiretroviral treatment group care in rural Mozambique found
92% adherence, mortality at just 2%, and that only 0.2% of
patients were lost to follow-up.
10 These excellent outcomes are
the result of a programme that encourages self sufficiency and
mutual support, a very different approach to the more usual
health worker intervention for adherence.
Agencies such as the AIDS Support Organization (TASO) and
the Family Treatment Fund in Uganda, as well as AMPATH in
Kenya, have long been aware of what drives adherence and
have launched initiatives that have included microfinance
opportunities, skills training, and drama groups to promote
positive living and encourage healthy social behaviours.
Can advances in technology help with adherence to treatment?
There is excitement about harnessing technology to provide
reminders,support,ormonitoringsystemsforadherence.
7Most
recently, mobile phones communications between health
workers and patients resulted in improved adherence and viral
suppression.
11 It is unclear whether improvements were due to
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EDITORIALSthe reminders or the support of health workers. Real time drug
adherence monitors, which record removal of a patient’s drug
bottle cap, are an innovative step towards monitoring patients
who are difficult to reach. Such monitors are unlikely to be
widely implemented because of high costs, and possible
opposition from patients, but they may be useful for patients
with specific challenges.
12 The use of technology to facilitate
social support may be a powerful approach.
Research into adherence to antiretroviral treatment should now
movetowardstestinginterventionsthatcouldmakeadifference.
Few randomised trials have evaluated support strategies and
their effects on adherence. However, because long term
adherence is necessary for treating HIV and preventing
transmission, and as funding becomes uncertain, it becomes
increasingly important to harness social capital because it is
cheap and adaptable to local environments, and it probably
offers the best return on investment in terms of conferring
clinically important health benefits.
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